Login
$ALLO
$0.81 +$0.00 (0.37%) After hours

$ALLO 8-K/A SEC Filings

Filed On Filing
17 Oct 2023 8-K/A: Departure/Election of Directors or Officers; Compensation

The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective O...

26 Oct 2020 8-K/A: Submission of Matters to a Vote of Security Holders

On June 5, 2020, Allogene Therapeutics, Inc. (the "Company") held its 2020 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 21, 2020, the record date for the Annual Meeting, 125,310,920 shares of common stock were outst...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support